Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome
复制标题
DOI：
10.2174/13816128113199990480
复制
发表时间：
2014-04-01
影响因子：
3.1
通讯作者：
Okuda, Seiya
中科院分区：
文献类型：
--
作者：
Ueda, Seiji;Yamagishi, Sho-ichi;Okuda, Seiya
肾综合征（CRS）是一种心血管疾病（CVD）和慢性肾脏疾病（CKD）之间存在复杂相互关系的疾病。一个器官的损伤可能会加速另一个器官的病理过程，这反过来又会加速两个器官衰竭的进展。虽然临床研究提示心血管系统和肾脏之间存在特定的双向相互作用，但对CRS的发病机制仍不清楚。可以解释这种联系的一个可能因素是内皮功能障碍（艾德）。艾德不仅参与动脉粥样硬化的发生和发展，而且还参与肾损伤的进展。不对称二甲基精氨酸（ADMA）是一种内源性NO合成酶抑制剂，存在于血浆和细胞中。CKD患者的血浆ADMA水平升高，已知是未来心血管事件以及CKD进展的独立生物标志物和预测因子。这些结果表明，积累的ADMA介导的艾德可能在CKD患者的CRS中起重要作用。本文就ADMA在艾德发展中的作用，特别是在CRS中的作用作一综述。
Cardiorenal syndrome (CRS) is a condition in which there is a complex interrelationship between cardiovascular disease (CVD) and chronic kidney disease (CKD). Impairment of one organ could accelerate pathological processes in the other, which in turn accelerates the progression of failure of both. Although clinical studies hint at a specific bidirectional interaction between cardiovascular system and kidney, insight into the pathogenesis of CRS remains unknown. One possible factor that could explain this link is endothelial dysfunction (ED). ED is not only involved in initiation and progression of atherosclerosis, but also contributes to progression of renal injury. Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase inhibitor found in the plasma and cells. Plasma ADMA levels are increased in CKD patients and known to be an independent biomarker and predictor for future cardiovascular events as well as the progression of CKD. These findings indicate that accumulated ADMA-mediated ED may play important roles in CRS in CKD patients. In this review, we discuss the roles of ADMA in the development of ED, especially focusing on its roles in CRS.